Amneal Pharmaceuticals (AMRX) Set to Announce Earnings on Thursday
Amneal Pharmaceuticals (NYSE:AMRX) will be posting its quarterly earnings results before the market opens on Thursday, February 28th. Analysts expect Amneal Pharmaceuticals to post earnings of $0.27 per share for the quarter.
NYSE AMRX opened at $13.47 on Thursday. The company has a quick ratio of 1.26, a current ratio of 1.91 and a debt-to-equity ratio of 2.92. The stock has a market cap of $4.10 billion, a PE ratio of 21.38, a P/E/G ratio of 0.51 and a beta of 1.38. Amneal Pharmaceuticals has a 52-week low of $11.66 and a 52-week high of $24.48.
AMRX has been the subject of several analyst reports. Zacks Investment Research cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. ValuEngine cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. Morgan Stanley cut shares of Amneal Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $24.00 to $18.00 in a research report on Friday, December 14th. Finally, Leerink Swann restated an “outperform” rating and issued a $19.00 target price (down from $25.00) on shares of Amneal Pharmaceuticals in a research report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $21.67.
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.